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Abstract
Objective: To investigate patients' preferences for outcomes associated with psychoactive medications.
Setting/design: Systematic review of stated preference studies. No settings restrictions were applied.
Participants/eligibility criteria: We included studies containing quantitative data regarding the relative
value adults with mental disorders place on treatment outcomes. Studies with high risk of bias were excluded.
Primary and secondary outcome measures: We restricted the scope of our review to preferences for
outcomes, including the consequences from, attributes of, and health states associated with particular
medications or medication classes, and process outcomes. Results: After reviewing 11 215 citations, 16
studies were included in the systematic review. These studies reported the stated preferences from patients
with schizophrenia (n=9), depression (n=4), bipolar disorder (n=2) and attention deficit hyperactive disorder
(n=1). The median sample size was 81. Side effects and symptom outcomes outnumbered functioning and
process outcomes. Severe disease and hospitalisation were reported to be least desirable. Patients with
schizophrenia tended to value disease states as higher and side effects as lower, compared to other stakeholder
groups. In depression, the ability to cope with activities was found to be more important than a depressed
mood, per se. Patient preferences could not consistently be predicted from demographic or disease variables.
Only a limited number of potentially important outcomes had been investigated. Benefits to patients were not
part of the purpose in 9 of the 16 studies, and in 10 studies patients were not involved when the outcomes to
present were selected. Conclusions: Insufficient evidence exists on the relative value patients with mental
disorders place on medication-associated outcomes. To increase patient-centredness in decisions involving
psychoactive drugs, further research-with outcomes elicited from patients, and for a larger number of
conditions-should be undertaken.
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ABSTRACT
Objective: To investigate patients’ preferences for
outcomes associated with psychoactive medications.
Setting/design: Systematic review of stated
preference studies. No settings restrictions were
applied.
Participants/eligibility criteria: We included
studies containing quantitative data regarding the
relative value adults with mental disorders place on
treatment outcomes. Studies with high risk of bias
were excluded.
Primary and secondary outcome measures: We
restricted the scope of our review to preferences for
outcomes, including the consequences from, attributes
of, and health states associated with particular
medications or medication classes, and process
outcomes.
Results: After reviewing 11 215 citations, 16 studies
were included in the systematic review. These studies
reported the stated preferences from patients with
schizophrenia (n=9), depression (n=4), bipolar disorder
(n=2) and attention deficit hyperactive disorder (n=1).
The median sample size was 81. Side effects and
symptom outcomes outnumbered functioning and
process outcomes. Severe disease and hospitalisation
were reported to be least desirable. Patients with
schizophrenia tended to value disease states as higher
and side effects as lower, compared to other
stakeholder groups. In depression, the ability to cope
with activities was found to be more important than a
depressed mood, per se. Patient preferences could not
consistently be predicted from demographic or disease
variables. Only a limited number of potentially
important outcomes had been investigated. Benefits to
patients were not part of the purpose in 9 of the 16
studies, and in 10 studies patients were not involved
when the outcomes to present were selected.
Conclusions: Insufficient evidence exists on the
relative value patients with mental disorders place on
medication-associated outcomes. To increase patient-
centredness in decisions involving psychoactive drugs,
further research—with outcomes elicited from patients,
and for a larger number of conditions—should be
undertaken.
Trial registration number: PROSPERO
CRD42013005685.
INTRODUCTION
To respect and respond to patient prefer-
ences is a crucial aim in patient-centred
healthcare1–3 and a persistent ideal in
evidence-based medicine,4 clinical practice
guidelines5 and shared decision-making.6
Integrating patient preferences is increas-
ingly advocated in health technology assess-
ments,7 drug development8 and market
approval and reimbursement.9 Yet to allow
patient preferences to guide healthcare deci-
sions remains to become common practice.10
In the mental health field, healthcare deci-
sions frequently involve medications: one in
five Americans and one in eight western
Europeans are prescribed psychotropic
drugs.11 12 The psychopharmacological
dilemmas faced by clinicians and patients are
often preference-sensitive, and involve trade-
offs of conflicting, multiple outcomes.13–15
Systematic reviews and meta-analyses have
summarised whether patients prefer pharma-
cological or psychological treatment,16 and
Strengths and limitations of this study
▪ This is the first systematic review on patients’
relative, stated preferences for outcomes of psy-
chopharmacological treatments across methods
and disorders.
▪ We summarised patients’ preferences for hypo-
thetical outcomes associated with medications
and excluded preferences for specific medica-
tions or treatment domains, which are amenable
to misconceptions. The treatments per se do not
give value to the user; it is their outcomes that
give value.
▪ We tested and applied a broad, peer reviewed
search strategy, but we might have overlooked or
missed studies. Study quality was rigorously and
comprehensively assessed.
▪ Owing to the heterogeneity of methods and out-
comes we could not perform quantitative sum-
maries of the relative strengths of preferences.
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the effect of matching the treatment to the patient’s pre-
ferred option.17 18 However, in trade-off dilemmas,
studies on patients’ preferred options might be less inform-
ative than studies on their preferences for the outcomes
of the options. Knowledge about the relative strengths of
preferences for treatment outcomes, representative for
populations, can be gained with stated preference
methods. A range of techniques is available.19–21
Systematic reviews of studies applying the techniques to
elicit patient preferences for outcomes of psychotropic
drugs are lacking. The current void of knowledge on the
outcomes patients value the most and least, and what
those outcomes should be,22 strikes the foundation of
patient-centred care and suggests missed opportunities
for more patient-centred decisions.
For these reasons we conducted a systematic review of
studies on patients’ valuations of outcomes associated
with psychoactive medications. The main goal was to
summarise what is known on the relative strengths of
preferences. We also reviewed:
▸ Whether patient perspectives were part of the
purpose and construction of outcomes
▸ Which outcomes were addressed
▸ The feasibility of stated preference methods for
patients with mental disorders
▸ Correlations between patient preferences and demo-
graphic or disease variables
▸ Differences between patients’ preferences and those
of other stakeholders
METHODS
This study followed the PRISMA reporting guidelines
(see online supplementary appendix 10): http://www.
plosmedicine.org/article/info%3Adoi%2F10.1371%
2Fjournal.pmed.1000097
Eligibility criteria
Studies applying stated preference methods to elicit the
relative values patients place on outcomes of psycho-
pharmacological treatments, using quantitative methods,
were eligible for inclusion. Studies that included rating
scales only were excluded due to doubts about whether
the techniques adequately measure strength of prefer-
ence.19 No publication date, context or publication
status restrictions were imposed.
We included studies on adult patients with direct
experience of the mental disorder specified in the study,
currently diagnosed with or at risk of recurrence of the
disease. Trials addressing patients with substance-related
and addictive disorders were excluded.
Patient preferences can be defined as “statements
made by individuals regarding the relative desirability of
a range of health experiences, treatment options, or
health states”.23 We restricted the scope of our review to
preferences for outcomes, including the consequences
from, attributes of, and health states associated with par-
ticular medications or medication classes and process
outcomes. Studies on patients’ preferences for specific
medications, medication classes, or treatment domains,
or for health states detached from a medication context,
were not included. Studies measuring health-related
quality of life were excluded unless they elicited patients’
relative valuations of outcomes.24 Studies calculating pre-
ferences by mapping life quality scales to utility scores
were not included. Owing to the heterogeneity of the
field, we did not specify the outcome measures in detail
before the study.
Search strategy
We searched Medline, Embase, PsycINFO, CENTRAL,
SveMed+, The Health Technology Assessment Database,
the NHS Economic Evaluation Database and grey litera-
ture databases from inception to September 2013. We
piloted our strategies in a test search and modified the
use of keywords and indexed terms. A PRESS (Peer
Review of Electronic Search Strategies) review was
undertaken and the strategies revised. In the revised
search, we used a combination of subject headings, sub-
headings and text words. The bibliographies of the
included studies were hand searched for additional
studies. Online supplementary appendix 1 details the
search strategies.
Study selection
Two review authors (KN, BFL) independently reviewed
all identified titles and abstracts (figure 1). Full text arti-
cles were obtained for potentially relevant trials and
examined in detail by the same authors. Disagreements
were discussed with the principal author (OE) and
resolved by consensus.
Quality assessment
Standardised criteria for methodological quality and risk
of bias in stated preference studies have not been estab-
lished.25 26 To enable critical appraisal, we constructed a
checklist based on criteria proposed for assessment of
stated preference research in eight methodological
reviews and evaluation tools.19 27–33 The resulting inven-
tory consisted of 31 quality criteria within five domains:
external validity, presentation of outcomes, minimisation
of irrelevant variance, reporting and analysis, and other
aspects (see online supplementary appendix 2). Two
authors (KN, OE) independently assessed all studies
considered for inclusion on the 31 items. Studies given
an overall intermediate or high quality rating were
included. Inconsistencies were resolved by discussion.
Data collection
We developed, piloted and revised a data extraction
form consistent with the goals of the review. Two
reviewers (KN, OE) independently extracted data on the
study, study population, preference elicitation aspects
and preference results (see online supplementary
appendix 3).
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RESULTS
Of 11 215 unique citations, 54 proceeded to full text
review. We excluded 39 studies, the most frequent reason
being lack of quantitative data on the relative strengths of
the preferences (see online supplementary appendix 4).
This left 16 studies for our systematic review. We present
the results in descriptive and tabular form.
Study characteristics
Sixteen studies in 16 papers included 1785 patients with
a median sample size of 81 (range 20–469). Nine studies
had assigned patients with schizophrenic disorders, four
had depressive disorders, two had bipolar disorders and
one had ADHD (attention deficit hyperactive disorder).
The range of reported mean ages was 39–46 and the
median percentage of female participants 55. In the
seven studies reporting ethnicity, the median percentage
of Caucasians was 86. Ten studies included only outpati-
ents, one inpatients and outpatients, and five did not
report hospitalisation status. Twelve of the 16 studies
were partly or fully conducted in the USA. Preference
elicitation was the main or part of the main objective in
15 studies. Preferences were elicited from patients with
the standard gamble (SG) method in six studies, con-
joint analysis (CA) and pair-wise comparison (PC) in
two studies each, discrete choice experiment (DCE) and
willingness-to-pay (WTP) in two, and time trade-off
(TTO) in one (table 1). Basic descriptions of the
methods are provided in box 1.
Study quality
A frequently used quality criterion for stated preference
studies is whether the outcomes are presented to the
participants in adequate detail.28 The level of detail
varied in the included studies, from short text descrip-
tions to info-graphics and videos with actors enacting
symptoms and side effects. All included studies mini-
mised threats on validity from factors irrelevant to the
represented outcomes using measures such as precom-
prehension or postcomprehension tests.
Non-random recruitment procedures limited the
external validity in all studies. Four studies included less
than 50 participants. In six studies, data were not
reported for participants who did not complete the pro-
cedures. Authors generally provided incomplete infor-
mation on study design, and five studies lacked measures
Figure 1 Flow chart of study
selection.
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of variance. The use of statistical techniques was deemed
appropriate in all studies. Only two studies were given
an overall ‘high quality’ rating (see online supplemen-
tary appendix 5).
Purposes
Seven studies related their results to potential benefits
for individual patients, for instance to tailor adherence
programmes,34 to be helpful in medical decision-
making35 or to promote concordance between patients
and psychiatrists.36 Although 13 of the studies received
funding from a pharmaceutical company, only five
studies suggested or performed economic analyses from
an industry perspective.37–41 Eight studies discussed how
their preference results could be used in public evalu-
ation and prioritisation contexts (see online supplemen-
tary appendix 6).
Outcome sources
In 10 of the 16 studies, input from patients was not
sought when outcomes were selected and constructed.
The six studies that obtained patients’ perspectives used
interviews,35 40 focus groups,36 42 piloting of the sug-
gested outcomes39 43 or comments on patient websites.40
In comparison, six studies engaged clinicians and 13
studies reported using research or literature to identify
the outcomes. Three used research or literature
only38 44 45 (see online supplementary appendix 6).
Included outcomes
Side effects (n=14) and symptoms including relapse
(n=11) were most frequently presented to participants.
Six studies included process related outcomes, for
instance, the treatment schedule, or number of visits to
the hospital. Functioning featured in six studies and
costs in three. While a large number of outcomes are
potentially relevant,25 only a limited number was pre-
sented in the studies. For example, mortality or burden
to relatives was not included in any study (see online
supplementary appendix 6 and 9).
Feasibility and validity
The studies reported that patients were able to provide
usable preference measures for the six methods applied,
generally comprehended the tasks and gave sufficiently
consistent answers. A total of 92–100% of the partici-
pants completed the procedures.
Three of the nine studies with patients with schizo-
phrenia reported moderate or major problems. In the
first, a small SG study, 30% of the patients did not
understand the survey well and 56% had inconsistent
rank ordering.46 In the second, also a SG study, patients
made more logical errors than others and mostly, in con-
trast to other stakeholders, preferred not to correct their
mistakes.28 In one of the two studies applying conjoint
analysis, patients reported lower levels of understanding
and more difficulty with the task compared to other par-
ticipants.45 Minor or no problems were reported in the
two schizophrenia studies applying TTO and self-
explicated methods.
The studies including patients with depression,
bipolar disorder and ADHD reported minor or no feasi-
bility problems, but feasibility and validity were less
focused on compared to the schizophrenia studies (see
online supplementary appendix 7).
Correlations with patient characteristics
Eleven studies investigated whether patient preferences
correlated with demographic or disease variables, with
negative or conflicting findings.
Three studies found that preferences correlated with
age,35 37 41 whereas five found no significant associ-
ation.38 40 42 43 47 Gender correlated with preferences in
one study,41 but did not correlate in four.35 38 40 47
Possible correlations with living arrangement, education,
employment-status and income level were investigated
with negative or mixed results.
Severity of disease correlated with preferences for
hypothetical health states43 47 and the impact of a side
effect on utility.28 Two studies40 42 found that disease
severity did not correlate with preferences, and one
study reported mixed results.43
Comparison with other stakeholder groups
Eight studies, all on schizophrenia, compared the prefer-
ences of patients with those of other stakeholder
groups.28 36 39 40 44–46 48 Patients’ preference values dif-
fered systematically from those of other stakeholders in
the five studies published after 1997, and the magnitude
of the differences varied from modest to consider-
able.28 36 40 44 45 People with schizophrenia valued
disease states higher than other stakeholder groups
did.28 40 44 Extrapyramidal side effects (EPS) were given
a lower value or deemed more important, compared to
clinicians,28 44 45 except in one study.48 The preferences
of family members were closer to those of patients, com-
pared to psychiatrists and laypeople, in studies that per-
formed relevant comparisons.28 44 48 Other stakeholders
did not value functioning or symptoms significantly
Box 1 Stated preference methods in healthcare
▸ The standard gamble elicits the value of outcomes by asking
patients to choose between a certain outcome and a gamble.
▸ Willingness to pay is the maximum amount a patient is willing
to offer to obtain good, or to avoid undesirable, outcomes.
▸ In conjoint analysis, patients place weights on different fea-
tures of a health option.
▸ In pairwise comparison, patients compare health options in
pairs to find which is preferred, or which has the largest
amount of a measurable aspect.
▸ In discrete choice experiments, patients state their preference
over alternative scenarios, such as health states.
▸ In time trade-off, patients are asked to choose between living
in a suboptimal state for a certain period of time, versus living
a healthier life for a shorter time.
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and/or consistently different from what patients did
(see online supplementary appendix 8).
Strengths of preferences
Stated preference methods elicit different preference
measures. WTP represents the value that an individual
places on a commodity, SG and TTO estimate a utility,
most often on a scale where 0 is death and 1 perfect
health. CA and DCE measure the relative importance or
value of different outcomes.19
Schizophrenia
‘Positive’, ‘acute’ or ‘psychotic’ symptoms figured consist-
ently among the least desirable outcomes to
patients.36 40 45 Negative symptoms such as reduced cap-
acity for emotion were found more desirable or less
important than positive symptoms.36 45 48
Independency was rated highly,36 45 and being an
inpatient, lowly.48 Cognitive36 42 and social36 42 45 func-
tions were moderately or highly important compared to
other outcomes. The importance of capacity for work
and for daily living was intermediate.36 42.45
EPS was included in seven studies. Two small
studies39 46 both reported that the disutility of parkin-
sonism was larger than the disutility of akathisia and
tardive dyskinesia. The presence of EPS reduced the
utility by 12–21%. Pseudoparkinsonism reduced the
utility with 5–7% in two other studies.28 44 In three add-
itional studies the relative importance of EPS was moder-
ate or high, compared to other outcomes.40 42 45 Health
states with weight gain had a higher utility than states
with EPS in the only schizophrenia study including side
effects other than EPS.40
Depression
Severe, untreated depression reduced the utility from
1.0 (perfect health) to 0.3, and 25% of patients consid-
ered this state equivalent to or worse than death.47
Patients’ reduced ability to start and cope with activities
on their own, due to fatigue, was more important than
depressed mood in one large, well-performed study.35
The same study found that side effects after 2 weeks also
were more important than depressed mood.35
The simultaneous presence of weight gain and no
orgasm reduced the WTP from USD 686 per month for
an antidepressant without side effects, to USD 227.41
One study found very small differences in side effect util-
ities.47 Patients were willing to pay more to avoid tremor
and sleepiness than to avoid dry mouth and sweating,
according to one study.38
Bipolar disorder
The inpatient state, inpatient mania and severe depres-
sion had lower utilities than the outpatient, stable state
in one study.43 The relative strengths of preferences for
mania versus depression were conflicting in two
studies.34 43 Cognitive effect and severity of depression
were equally important in one study.34
Weight gain within 3 months was found to be equally
important to cognitive impairment and severity of
depression, and three times more important than
serious side effects34 A weight gain of more than 2.3 kg
reduced the utility with 0.07.43
ADHD
Patients were willing to pay 74% more for functioning
well in the morning and school/workday, compared to
functioning well in the afternoon/evening in one
study.37
Table 2 and online supplementary appendix 9 contain
additional details on all the conditions.
DISCUSSION
Principal findings
Benefits to patients and clinical practice were part of the
purpose in a minority of the 16 studies included in this
review. Most authors had not involved patients when
they selected and developed the outcomes in their
studies. Side effect and symptom outcomes outnum-
bered functioning and process outcomes, and only a
limited selection of potentially important outcomes were
presented to patients. The stated preference methods
were generally found to be feasible across different con-
ditions and disease severities, but patients with schizo-
phrenia experienced more problems with the tasks than
other patient groups, in particular for SG. The patients’
preferences did not vary consistently with age, gender,
disease severity or other demographic or disease vari-
ables. The relative preferences of patients with schizo-
phrenia differed systematically from those of other
stakeholders in most studies. Patients valued disease
states higher than did other groups and perceived side
effects more negatively than clinicians did. Patients with
schizophrenia desired acute and psychotic symptoms
least of all outcomes, and valued independency highly.
Functioning occupied a middle ground; social function
tended to be more important than vocational function.
The importance of EPS was moderate or high. For
patients with depression, severe disease greatly reduced
utility, though the ability to cope with activities, and pres-
ence of side effects, appeared more important than a
depressed mood, per se. Patients with bipolar disorder
valued inpatient mania and severe depression lowly, and
reported weight gain to be important. In ADHD,
patients reported that functioning in the morning and
during daytime was most important.
Strengths and weaknesses of the review
This is the first systematic review on patients’ relative,
stated preferences for outcomes of psychopharmaco-
logical treatments across methods and disorders. The
review accords with the PRISMA guidelines (see online
supplementary appendix 10) and the protocol was regis-
tered in the PROSPERO database prior to conduction
(see online supplementary appendix 11).
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We summarised patients’ preferences for outcomes
associated with medications and excluded preferences
for specific medications or treatment domains, which
are amenable to misconceptions. The treatments do not
give value to the user, per se; it is their outcomes that
give value.49 In a trade-off situation, the best option
reflects the partial valuations and probabilities of those
outcomes.50
Preference studies are not archived in reference data-
bases with common subject headings and keywords that
allow a highly sensitive and specific retrieval.25 We tested
and applied a broad, peer reviewed search strategy, but
we might have overlooked or missed studies.
We rigorously and comprehensively assessed study
quality. Several included studies risked multiple biases
and stricter criteria could have been applied. However,
quality criteria for preference studies can conflict and
methodological rigour must be balanced with the cogni-
tive effort demanded from participants.
Owing to the heterogeneity of methods and outcomes,
we could not perform quantitative summaries of the rela-
tive strengths of preferences, as is common in systematic
reviews on preference studies.26 51 52 Our review includes
studies that were not powered to provide statistically signifi-
cant differences for strengths of preferences. Preferences
for outcomes were elicited from varying and often small
numbers of participants, with heterogeneous disorders.
The end of the search period was September 2013,
thus at the time of publication the search is relatively old
in comparison to the median for systematic reviews.53 54
Stated preference studies elicit preferences in hypo-
thetical choices, and the outcome preferences in a real
setting might be different. The reliability and validity of
specific patient preference methods is debated, and the
techniques and quality standards are likely to change in
the future.21 55 56
Results in context
The call for outcomes that are meaningful and import-
ant to patients is increasing57 58 Patient-centred out-
comes are often contrasted to clinical outcomes such as
symptom control and side effects. They assess the impact
of illness and therapy from patients’ perspectives, and
should be those that patients notice and care about.59
In contrast to this aim, we found that outcomes pre-
sented for preference elicitation were mostly selected
and described without input from patients. Other sys-
tematic reviews on stated preferences confirm this
finding. In a review of experiences of healthcare deliv-
ery, few outcomes were worded from patients’ perspec-
tives.21 In a review on diabetes care, only 3 of 14 studies
had employed focus groups in the outcome selection
process.52 Disease-specific reviews often do not report
on patient involvement.26 51 60 In line with this lack of
patient-centredness and similar to our findings,
symptom outcomes and adverse effects are most fre-
quently included in preference studies, at the expense
of other outcomes.25
Suggested patient-centred outcomes in mental disor-
ders include social and vocational functioning, body
image, reduced stigma, recovery and reduced burden to
caregivers.22 In schizophrenia alone, 194 non-traditional
outcomes have been suggested.61 We found that side
effects and in particular EPS and weight gain were
important to patients, both relative to other outcomes
and to other stakeholders. Side effects have an impact
on health status, but to patients, their effect on physical
attractiveness and the associated status, self-esteem and
social opportunity might be more important.62 When
the functional consequences of adverse events and no
treatment are similar, people value avoiding the adverse
effects most.51
In addition to side effects, severe symptoms were
highly important to patients, whereas functioning was
moderately important. The claim that patients value
functioning higher than symptom-oriented, ‘textbook’
outcomes, was therefore not supported.36
We found significant differences in how patients and
non-patients valued outcomes. This topic is currently
debated. Accordant with our findings, the most compre-
hensive meta-analysis to date63 concluded that patients
value health states higher than the general public. The dif-
ference was small to moderate, and notably the valuations
differed less when both groups valued descriptions of health
states, instead of patients valuing their actual health. A pos-
sible explanation for a difference is that people adapt
when they become ill: we develop skills, adjust activities and
expectations, and redefine what is good health and a good
life.55 64 65 Notably, different valuations of one-dimensional
health states do not necessarily translate to differing partial
utilities of health states and to process outcomes.66
Concerns have been raised that cognitive impairment,
limited self-insight and distortions of reality impede
patients’ use of stated preferences methods, and could
leave the results meaningless, in particular in schizo-
phrenia.67 68 The results of the studies in this review
indicate that several stated preference methods might be
feasible for identifying relative outcome preferences
from patients with mental disorders, and that validity is
comparable to other stakeholder groups. In a systematic
review, the practicality of TTO and CV (contingent valu-
ation) was found to be generally good in patients with
depression and schizophrenia. Two of the four studies in
the review reported that patients with schizophrenia had
some difficulties with the SG tasks.69 The need to
improve the techniques persists.70
Meaning of study
Patients report that being told the risks and benefits of
treatments is one of the 10 most important aspects of
healthcare.71 However, which risks and benefits clini-
cians communicate to patients is a matter of choice.
This review highlights outcomes and outcome priorities
clinicians should consider bringing into their conversa-
tions with patients when they discuss and decide
between psychotropic drug options.
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Our findings could inform on the benefits and harms
to include in patient decision aids, which are tools
designed to help patients participate in making choices
among healthcare options.72
It has been suggested that authors of clinical guidelines
should conduct a systematic review on patient prefer-
ences in the relevant content area.28 51 The stated prefer-
ences presented in this review could be used as an early
point of reference when guidelines are developed for
schizophrenia, depression, bipolar disorder and ADHD.
In situations where stakeholder groups have different
values, spotlighted in this review, a main question is whose
preferences should be accommodated? Proponents of the
patients’ preferences argue that people with the relevant
disease are the best judges of their own welfare, and that
true preferences require experience with the outcome.
Opponents claim that the judgments of non-patients are
more appropriate, because decisions affecting resource
allocation for one group of patients affect the provision for
other groups.55 The dilemma is not empirical, but norma-
tive, and the answer depends on the decision context.55 73
In economic assessments, the relative preferences
from patients reported in this review might inform regu-
latory benefit-risk assessments and be used in direct
comparisons of drugs,9 but in this field, the preferences
of the general population is currently the norm.74
Unanswered questions and implications for research
Although many studies have addressed ‘what matters’ to
patients with mental disorders, few have investigated the
relative preferences for medication outcomes. Current
knowledge is fragmented and exists for a limited
number of aspects and conditions only. Surprisingly,
only a minority of the studies have been performed
from patients’ perspectives. The evidence does not allow
firm conclusions on what outcomes of psychotropic
medications matter most to patients, and there is an
obvious need for more research.
Insufficient reporting in stated preference studies is
widespread.51 52 60 Concise reporting of all study dimen-
sions, including variance, study design and the outcome
descriptions presented to patients, is necessary.
Although the studies in this review generally found that
stated preference methods were feasible for patients
with mental health disorders, challenges were also
exposed, demonstrating that the techniques need to be
improved and tailored to the relevant populations.
CONCLUSION
Despite the widely declared prominence of patient pre-
ferences in healthcare, knowledge on which medication-
related outcomes matter most to patients with mental
health disorders has been largely absent. Clinicians and
policymakers should be aware that patients’ priorities
might be different from theirs and that they cannot reli-
ably be inferred from patients’ demographic character-
istics or health status. To improve health outcomes for
patients, we need more evidence on the relative import-
ance patients place on relevant outcomes. In clinical
practice, knowledge on group-level preferences can be a
starting point, but to know what matters most to the
person in front of you, you have to ask.
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